Hoppa till innehållet

OMXSPI+0,50%

S&P 500+0,80%

FTSE 100+0,54%

DAX+0,01%

NIKKEI+1,14%
Redeye: ADDvise Q1 2024 - Organic growth set to start improving in H2 2024e

Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which featured weaker Healthcare sales and margins than we had anticipated. Lab’s first-quarter figures roughly aligned with our expectations. We judge organic growth should start improving in H2 2024e. We nudge down our estimates and valuation, though our long-term view of the equity story remains unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

ADDvise Q1 2024 - Organic growth set to start improving in H2 2024e

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera